.png){kind=icon}
传染病药物开发
揭示未满足传染病需求的解决方案。
By attacking infectious diseases together, we will find new cures.
访问我们在病毒、细菌、真菌和寄生虫病和疫苗开发方面的全球经验。
利用我们的综合临床前和临床发现加速您的传染病计划。yaboapp体育官网
Capitalize on unique insights from more than 150 infectious disease studies with over 17,000 patients.
Driving global success in infectious disease.
Today, unmet needs are driving global demand for safer, more robust and efficacious infectious disease drugs. Unfortunately, many factors challenge the discovery of global solutions — factors like global mobility, the rapid emergence of antibiotic resistance and the rise of hospital acquired infections. Our successful experience in developing infectious disease solutions leverage unique thinking and capabilities that span preclinical and clinical capabilities across the areas of bacterial, viral, fungal and parasitic diseases. In fact, we’ve worked on more than 150 infectious disease studies — including three of the last four antibiotics approved — and leverage this expertise to shape new opportunities for you.
破解疫苗和抗感染药物研发的复杂挑战。
从选择最合适的动物模型系统到获取疫苗抗原的免疫原性信息，再到确定对疫苗成功至关重要的特性，我们确保您提交的分子监管报告是可靠的。而且，如果您需要通过集成实验室和微生物学服务快速启动大型全球试验项目，我们拥有专业知识，可以根据您的关键里程碑迅速交付。
获取经验证的特性良好的感染性挑战剂库存，以评估预防性和治疗性疫苗和抗感染药物
充分利用我们重要的BSL-1和BSL-2遏制设施，这些设施是AAALAC认证、美国农业部注册和OLAW保证的
开发运输解决方案并准备定制MIC板，以测试新研究药物的敏感性
Attacking viruses using insight and expertise.
Hepatitis C is a significant medical challenge that we’re actively partnering to cure. With research rapidly advancing and new treatment paradigms the competitive landscape of new drugs in development requires rapid testing to provide both medical and economic proof of efficacy. In addition, we have successfully brought multiple influenza and HIV solutions to market. From genomics to clinical development to safety and viral testing in our central laboratories, we are relentless in our promise to provide you guidance and help deliver solutions made real.
一套针对相关疾病的创新解决方案，最大限度地提高您的发展预算价值。
我们为您的传染病发展提供全套服务。从临床前免疫学研究到概念验证，再到全球临床试验，我们的目标是利用我们丰富的科学和操作经验为您造福。我们很早就整合了我们的服务，以帮助您最大限yaboapp体育官网度地提高您的研究行为，以及您的分子投资回报率。